$2.45 Billion is the total value of Artal Group S.A.'s 110 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS INC | $334,939,000 | -16.3% | 60,240,864 | 0.0% | 13.68% | -7.7% | |
| WW | WEIGHT WATCHERS INTL INC NEW | $298,589,000 | -47.7% | 14,818,300 | 0.0% | 12.19% | -42.4% | |
| BGNE | BEIGENE LTDsponsored adr | $79,200,000 | -5.9% | 600,000 | 0.0% | 3.23% | +3.8% | |
| BABA | ALIBABA GROUP HLDG LTDsponsored ads | $75,169,000 | +33.1% | 412,000 | 0.0% | 3.07% | +46.7% | |
| RUBY | RUBIUS THERAPEUTICS INC | $52,650,000 | +12.6% | 2,908,791 | 0.0% | 2.15% | +24.1% | |
| GS | GOLDMAN SACHS GROUP INCcall | $47,998,000 | +14.9% | 250,000 | 0.0% | 1.96% | +26.7% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $26,976,000 | +46.3% | 400,000 | 0.0% | 1.10% | +61.3% | |
| PRQR | PROQR THRAPEUTICS N V | $19,418,000 | -12.1% | 1,400,000 | 0.0% | 0.79% | -3.1% | |
| ALBO | ALBIREO PHARMA INC | $16,105,000 | +31.3% | 500,000 | 0.0% | 0.66% | +44.9% | |
| XNCR | XENCOR INC | $15,530,000 | -14.1% | 500,000 | 0.0% | 0.63% | -5.4% | |
| AGIO | AGIOS PHARMACEUTICALS INCcall | $13,488,000 | +46.3% | 200,000 | 0.0% | 0.55% | +61.1% | |
| ALLO | ALLOGENE THERAPEUTICS INC | $11,564,000 | +7.4% | 400,000 | 0.0% | 0.47% | +18.3% | |
| ZGNX | ZOGENIX INC | $11,002,000 | +50.9% | 200,000 | 0.0% | 0.45% | +66.3% | |
| AXDX | ACCELERATE DIAGNOSTICS INC | $10,510,000 | +82.8% | 500,000 | 0.0% | 0.43% | +101.4% | |
| RGNX | REGENXBIO INC | $9,743,000 | +36.6% | 170,000 | 0.0% | 0.40% | +50.8% | |
| XLRN | ACCELERON PHARMA INCcall | $9,314,000 | +6.9% | 200,000 | 0.0% | 0.38% | +17.6% | |
| VICI | VICI PPTYS INC | $8,752,000 | +16.5% | 400,000 | 0.0% | 0.36% | +28.4% | |
| AGEN | AGENUS INC | $8,168,000 | +24.8% | 2,750,000 | 0.0% | 0.33% | +38.0% | |
| SPRO | SPERO THERAPEUTICS INC | $7,686,000 | +108.3% | 600,000 | 0.0% | 0.31% | +129.2% | |
| RCKT | ROCKET PHARMACEUTICALS INC | $7,016,000 | +18.4% | 400,000 | 0.0% | 0.29% | +30.0% | |
| FOLD | AMICUS THERAPEUTICS INCcall | $6,800,000 | +42.0% | 500,000 | 0.0% | 0.28% | +57.1% | |
| TBIO | TRANSLATE BIO INC | $6,114,000 | +35.9% | 600,000 | 0.0% | 0.25% | +49.7% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $5,179,000 | +25.0% | 145,000 | 0.0% | 0.21% | +37.9% | |
| STML | STEMLINE THERAPEUTICS INC | $5,140,000 | +35.3% | 400,000 | 0.0% | 0.21% | +48.9% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $4,755,000 | +7.5% | 500,000 | 0.0% | 0.19% | +18.3% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $4,552,000 | -24.1% | 200,000 | 0.0% | 0.19% | -16.2% | |
| ADRO | ADURO BIOTECH INC | $3,980,000 | +50.8% | 1,000,000 | 0.0% | 0.16% | +66.3% | |
| AKBA | AKEBIA THERAPEUTICS INC | $3,890,000 | +48.1% | 475,000 | 0.0% | 0.16% | +63.9% | |
| SGMO | SANGAMO THERAPEUTICS INC | $3,816,000 | -16.9% | 400,000 | 0.0% | 0.16% | -8.2% | |
| RCUS | ARCUS BIOSCIENCES INC | $3,747,000 | +16.0% | 300,000 | 0.0% | 0.15% | +27.5% | |
| Z | ZILLOW GROUP INCcl c cap stk | $3,474,000 | +10.0% | 100,000 | 0.0% | 0.14% | +21.4% | |
| TWST | TWIST BIOSCIENCE CORP | $3,477,000 | +0.4% | 150,000 | 0.0% | 0.14% | +10.9% | |
| MGTA | MAGENTA THERAPEUTICS INC | $3,294,000 | +188.9% | 200,000 | 0.0% | 0.14% | +221.4% | |
| YI | 111 INCads | $2,921,000 | +5.7% | 450,000 | 0.0% | 0.12% | +16.7% | |
| TORC | RESTORBIO INC | $2,728,000 | -20.9% | 400,000 | 0.0% | 0.11% | -13.3% | |
| GRTS | GRITSTONE ONCOLOGY INC | $2,660,000 | -13.9% | 200,000 | 0.0% | 0.11% | -4.4% | |
| AVRO | AVROBIO INC | $2,205,000 | +32.4% | 100,000 | 0.0% | 0.09% | +45.2% | |
| ZFGN | ZAFGEN INC | $1,918,000 | -44.6% | 700,000 | 0.0% | 0.08% | -39.1% | |
| MGEN | MIRAGEN THERAPEUTICS INC | $1,395,000 | -7.9% | 500,000 | 0.0% | 0.06% | +1.8% | |
| ARPO | AERPIO PHARMACEUTICALS INC | $1,404,000 | -47.0% | 1,558,400 | 0.0% | 0.06% | -41.8% | |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $1,252,000 | +9.3% | 110,532 | 0.0% | 0.05% | +21.4% | |
| NVLNF | NOVELION THERAPEUTICS INC | $315,000 | +46.5% | 256,400 | 0.0% | 0.01% | +62.5% | |
| TRILLIUM THERAPEUTICS INC | $99,000 | -61.5% | 150,000 | 0.0% | 0.00% | -60.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.